Semaglutide for weight loss: Where is the weight loss coming from? A systematic review and meta-analysis

Lead Investigator: Bryan Saunders, University of Sao Paulo
Title of Proposal Research: Semaglutide for weight loss: Where is the weight loss coming from? A systematic review and meta-analysis
Vivli Data Request: 10732
Funding Source: None
Potential Conflicts of Interest: None

Summary of the Proposed Research:

Obesity is a growing health concern that affects millions of people around the world. It is linked to various diseases, such as diabetes, heart disease, and certain cancers. Many individuals struggle with weight loss, which can lead to significant health issues. One treatment option that has gained attention is Semaglutide, a medication that helps lower blood sugar levels and reduce hunger, leading to weight loss.

While Semaglutide has proven effective for helping people lose weight, it’s important to understand that not all weight loss is the same. When individuals lose weight, they may lose both fat and muscle. The main goal of any weight loss program should be to lose fat while preserving muscle mass, as maintaining muscle is vital for overall health and metabolism. However, it remains unclear how much of the weight lost while taking Semaglutide comes from fat versus muscle.

This research project aims to find out what portion of the weight loss experienced by individuals taking Semaglutide is due to the loss of muscle or lean mass. To achieve this, we will conduct a systematic review and meta-analysis. This means we will collect and analyze data from various studies that have previously investigated the effects of Semaglutide on weight loss. By combining the findings from these studies, we hope to provide a clearer picture of how Semaglutide affects fat and muscle loss.

Understanding how Semaglutide contributes to weight loss is crucial for improving patient care. By determining the balance between fat and muscle loss, healthcare providers can better guide their patients in making informed decisions about their weight loss strategies. This research will not only add valuable knowledge to the field of obesity treatment but will also help in the development of more effective weight management programs.

Requested Studies:

The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
Data Contributor: Lilly
Study ID: NCT03951753
Sponsor ID: 17091